Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 11203

1.

Targets for future clinical trials in Huntington's disease: What's in the pipeline?

Wild EJ, Tabrizi SJ.

Mov Disord. 2014 Aug 25. doi: 10.1002/mds.26007. [Epub ahead of print]

PMID:
25155142
[PubMed - as supplied by publisher]
2.

Genetic modifiers of Huntington's disease.

Gusella JF, MacDonald ME, Lee JM.

Mov Disord. 2014 Aug 25. doi: 10.1002/mds.26001. [Epub ahead of print]

PMID:
25154728
[PubMed - as supplied by publisher]
3.

Variability in interval production is due to timing-dependent deficits in Huntington's disease.

Rao AK, Marder KS, Uddin J, Rakitin BC.

Mov Disord. 2014 Aug 22. doi: 10.1002/mds.25998. [Epub ahead of print]

PMID:
25154339
[PubMed - as supplied by publisher]
4.

The role of iron in gray matter degeneration in Huntington's disease: A magnetic resonance imaging study.

Sánchez-Castañeda C, Squitieri F, Di Paola M, Dayan M, Petrollini M, Sabatini U.

Hum Brain Mapp. 2014 Aug 21. doi: 10.1002/hbm.22612. [Epub ahead of print]

PMID:
25145324
[PubMed - as supplied by publisher]
5.

Reduced Motivation in the BACHD Rat Model of Huntington Disease Is Dependent on the Choice of Food Deprivation Strategy.

Jansson EK, Clemens LE, Riess O, Nguyen HP.

PLoS One. 2014 Aug 21;9(8):e105662. doi: 10.1371/journal.pone.0105662. eCollection 2014.

PMID:
25144554
[PubMed - in process]
Free PMC Article
6.

Two-point magnitude MRI for rapid mapping of brown adipose tissue and its application to the r6/2 mouse model of huntington disease.

Lindenberg KS, Weydt P, Müller HP, Bornstedt A, Ludolph AC, Landwehrmeyer GB, Rottbauer W, Kassubek J, Rasche V.

PLoS One. 2014 Aug 21;9(8):e105556. doi: 10.1371/journal.pone.0105556. eCollection 2014.

PMID:
25144457
[PubMed - in process]
Free PMC Article
7.

Chemo-predictive assay for targeting cancer stem-like cells in patients affected by brain tumors.

Mathis SE, Alberico A, Nande R, Neto W, Lawrence L, McCallister DR, Denvir J, Kimmey GA, Mogul M, Oakley G, Denning KL, Dougherty T, Valluri JV, Claudio PP.

PLoS One. 2014 Aug 21;9(8):e105710. doi: 10.1371/journal.pone.0105710. eCollection 2014.

PMID:
25144312
[PubMed - in process]
Free PMC Article
8.

Onset of Huntington's disease: Can it be purely cognitive?

Paulsen JS, Long JD.

Mov Disord. 2014 Aug 20. doi: 10.1002/mds.25997. [Epub ahead of print]

PMID:
25142616
[PubMed - as supplied by publisher]
9.

Longitudinal resting state fMRI analysis in healthy controls and premanifest Huntington's disease gene carriers: A three-year follow-up study.

Odish OF, van den Berg-Huysmans AA, van den Bogaard SJ, Dumas EM, Hart EP, Rombouts SA, van der Grond J, Roos RA; on behalf of the TRACK-HD Investigator Group.

Hum Brain Mapp. 2014 Aug 19. doi: 10.1002/hbm.22616. [Epub ahead of print]

PMID:
25139578
[PubMed - as supplied by publisher]
10.

Instability of Trinucleotidic Repeats During Chromatin Remodeling in Spermatids.

Simard O, Grégoire MC, Arguin M, Brazeau MA, Leduc F, Marois I, Richter MV, Boissonneault G.

Hum Mutat. 2014 Aug 18. doi: 10.1002/humu.22637. [Epub ahead of print]

PMID:
25136821
[PubMed - as supplied by publisher]
11.

Genetic rescue of CB1 receptors on medium spiny neurons prevents loss of excitatory striatal synapses but not motor impairment in HD mice.

Naydenov AV, Sepers MD, Swinney K, Raymond LA, Palmiter R, Stella N.

Neurobiol Dis. 2014 Aug 15. pii: S0969-9961(14)00240-X. doi: 10.1016/j.nbd.2014.08.009. [Epub ahead of print]

PMID:
25134728
[PubMed - as supplied by publisher]
12.

Expression, pharmacology and functional activity of adenosine A<sub>1</sub> receptors in genetic models of Huntington's disease.

Ferrante A, Martire A, Pepponi R, Varani K, Vincenzi F, Ferraro L, Beggiato S, Tebano MT, Popoli P.

Neurobiol Dis. 2014 Aug 15. pii: S0969-9961(14)00244-7. doi: 10.1016/j.nbd.2014.08.013. [Epub ahead of print]

PMID:
25132555
[PubMed - as supplied by publisher]
13.

Clinimetric properties of the Tinetti Mobility Test, Four Square Step Test, Activities-specific Balance Confidence Scale, and spatiotemporal gait measures in individuals with Huntington's disease.

Kloos AD, Fritz NE, Kostyk SK, Young GS, Kegelmeyer DA.

Gait Posture. 2014 Jul 28. pii: S0966-6362(14)00654-7. doi: 10.1016/j.gaitpost.2014.07.018. [Epub ahead of print]

PMID:
25128156
[PubMed - as supplied by publisher]
14.

Repurposing human PDE4 inhibitors for neglected tropical diseases: Design, synthesis and evaluation of cilomilast analogues as Trypanosoma brucei PDEB1 inhibitors.

Amata E, Bland ND, Hoyt CT, Settimo L, Campbell RK, Pollastri MP.

Bioorg Med Chem Lett. 2014 Sep 1;24(17):4084-9. doi: 10.1016/j.bmcl.2014.07.063. Epub 2014 Jul 30.

PMID:
25127163
[PubMed - in process]
15.

Metabolism in HD: Still a relevant mechanism?

Duan W, Jiang M, Jin J.

Mov Disord. 2014 Aug 13. doi: 10.1002/mds.25992. [Epub ahead of print]

PMID:
25124273
[PubMed - as supplied by publisher]
16.

Cerebellar abnormalities in Huntington's disease: A role in motor and psychiatric impairment?

Rees EM, Farmer R, Cole JH, Haider S, Durr A, Landwehrmeyer B, Scahill RI, Tabrizi SJ, Hobbs NZ.

Mov Disord. 2014 Aug 13. doi: 10.1002/mds.25984. [Epub ahead of print]

PMID:
25123926
[PubMed - as supplied by publisher]
17.

Chronic cannabinoid receptor stimulation selectively prevents motor impairments in a mouse model of Huntington's disease.

Pietropaolo S, Bellocchio L, Ruiz-Calvo A, Cabanas M, Du Z, Guzmán M, Garret M, Cho YH.

Neuropharmacology. 2014 Aug 11. pii: S0028-3908(14)00283-4. doi: 10.1016/j.neuropharm.2014.07.021. [Epub ahead of print]

PMID:
25123645
[PubMed - as supplied by publisher]
18.

Correlation between human maternal-fetal placental transfer and molecular weight of PCB and dioxin congeners/isomers.

Mori C, Nakamura N, Todaka E, Fujisaki T, Matsuno Y, Nakaoka H, Hanazato M.

Chemosphere. 2014 Nov;114:262-7. doi: 10.1016/j.chemosphere.2014.04.095. Epub 2014 May 29.

PMID:
25113211
[PubMed - in process]
19.

Benign Hereditary Chorea: A Case Report and Brief Review of Inherited Choreas.

Kumar G, Dixon A.

Pediatr Neurol. 2014 Jun 8. pii: S0887-8994(14)00338-5. doi: 10.1016/j.pediatrneurol.2014.06.001. [Epub ahead of print]

PMID:
25108317
[PubMed - as supplied by publisher]
20.

Heterozygous Igf1r deletion does not ameliorate pathological features associated with polyglutamine-containing huntingtin fragment.

Jakubik M, Floriddia EM, Nicotera P, Bano D.

Neurosci Lett. 2014 Aug 4;580C:52-55. doi: 10.1016/j.neulet.2014.07.049. [Epub ahead of print]

PMID:
25102325
[PubMed - as supplied by publisher]

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Loading ...
Write to the Help Desk